K

Mirae Asset Venture Investment logo

Mirae Asset Venture Investment

Crunchbase
Pitchbook
Crunchbase

Deals on record

8

Common Fundraising Type

Series B

RLWRLD logo
RLWRLD

AI models • Robotics

Mirae Asset Venture Investment logo
Hashed logo
Global Brain logo

RLWRLD develops foundational AI models to enable robots to autonomously perform complex tasks with advanced dexterity in dynamic environments.

Seed
$14.8M
04/15/2025
Article
ACT-ion logo
ACT-ion

Battery technology • Lithium battery

Mirae Asset Capital logo
LG Technology Ventures logo
Hunt Energy Enterprises logo
BASF Venture Capital logo

ACT-ion is a battery technology company specializing in the production of coated single crystal lithium battery cathode active materials through an energy and cost-efficient process.

Series A
$7.5M
02/10/2025
Article
858 Therapeutics logo
858 Therapeutics

Biotechnology • Small molecule therapeutics

Avidity Partners logo
Versant Ventures logo
NEA logo
Mirae Asset Capital logo

858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.

Series B
$50M
09/26/2024
Article
Sri Mandir logo
Sri Mandir

Devotional app • Virtual prayers

Susquehanna Asia VC logo
Peak XV logo
Mirae Asset VC logo
Fundamentum Partnership logo

AppsForBharat develops and operates Sri Mandir, a devotional app that facilitates virtual prayers, donations, and religious tourism, primarily targeting the Indian and Indian-American communities.

Series B
$18M
09/10/2024
Article
ON logo
ON

AI chat platform • Generative AI

Mirae Asset Venture Investment logo
Equiam logo
Commonwealth Financial Network logo
B3 Capital logo

ON is a San Francisco-based AI chat platform that specializes in delivering generative AI experiences to major brands and sports teams, and is expanding into e-commerce, consumer banking, healthcare, and publishing sectors.

Equity
$25M
12/06/2023
Article
ROME Therapeutics logo
ROME Therapeutics

Biotechnology • Autoimmune Diseases

Section 32 logo
Sanofi Ventures logo
Raycap logo
Mirae Asset Capital logo

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Series B
$72M
09/12/2023
Article
d-Matrix logo
d-Matrix

Generative AI • Data Centers

Playground Global logo
M12 logo
TGC Square logo
Temasek logo

d-Matrix is a company that develops generative AI compute solutions for data centers, specifically focusing on addressing memory bottlenecks and reducing AI compute costs through its Digital-In Memory Compute (DIMC) chiplet-based inference compute platform.

Series B
$110M
09/06/2023
Article
Sapeon logo
Sapeon

AI Semiconductor • Hyper-Cloud Processor

We Ventures logo
Mirae Asset Venture Investment logo
Hana Financial Group logo
E1 logo

Sapeon is a South Korea-based AI semiconductor company that develops a hyper-cloud AI processor designed to efficiently process large amounts of data simultaneously while using less power.

Series A
$45M
09/01/2023
Article